Gedeon Richter Plc.
- Introduction
- Trading data
- Financials
- Shareholders, management
- Publications
- Product features
| Full Name | Chemical Works of Gedeon Richter Plc. | |||||||||
| Short name | Gedeon Richter Plc. | |||||||||
| Sector | Pharmaceuticals | |||||||||
| Contact |
HU-1103 Budapest, Gyömrői út 19-21.
Phone: +36-1-431-4027
Fax: -
|
|||||||||
| Investor Relations | ||||||||||
| Auditor | Deloitte Co. Ltd. | |||||||||
| Business activity | Founded in 1901 by Gedeon Richter, the plant was transformed into a business entity in 1923. Since 1997, it has been the largest domestic drug manufacturer. Its main activity is the manufacturing and distribution of active ingredients and generic pharmaceuticals. Richter has now grown into a multinational company of the Central and Eastern European region. Due to a market network unique in the region and covering five continents, the company s products are available in nearly one hundred countries worldwide. Also unique among Hungarian companies is its network of market interests, comprising the member states of the European Union, the United States of America, the CIS states, Japan and the Eastern region. It operates an extensive marketing and distribution network in Hungary, the CIS states and Eastern Europe. | |||||||||
| Listed securities of the issuer |
|
| Basic Information | |
|---|---|
| Ticker | RICHTER |
| ISIN | HU0000123096 |
| Date of listing | 09 Nov 1994 |
| Currency of trading | HUF |
| Face Value | 100 HUF |
| Number of securities listed | 186,374,860 |
| Market Capitalisation (HUF million) | 1,955,072 |
| > Split (S)/Reverse split (R) | |
|---|---|
| 11 Jul 2013 | S (1 : 10) |
| P/BV | |
|---|---|
| P/BV* | 1.5014 |
* Calculating based on the capitalisation of the actual series only
| Performance | |
|---|---|
* annualized yield
Key annual data
audited, consolidated, IFRS; Business Year: January 1 - December 31| 20231 | 20241 | |
|---|---|---|
| (million HUF) | (million HUF) | |
| Total revenues | 805,158 | 857,545 |
| Operating Profit (EBIT) | 189,364 | 261,157 |
| Net income from financial activities | -23,958 | 12,902 |
| Profit before tax | 171,540 | 281,077 |
| Profit after tax | 160,651 | 239,524 |
| Dividend per (ordinary) share | 431.98 HUF | HUF |
| Fixed Assets | 826,304 | 961,934 |
| Total liabilities | 218,636 | 299,129 |
| Share capital | 18,636 | 18,638 |
| Shareholders equity | 1,142,581 | 1,303,862 |
| Total assets | 1,361,217 | 1,602,991 |
| Number of employees (at business year end) | 11,603 | 11,757 |
- (1) audited, consolidated, IFRS; Business Year: January 1 - December 31
Selected financial ratios
Ratios are based on data submitted by the company| 2023 | 2024 | |
|---|---|---|
| Equity Ratio | 0.19 | 0.23 |
| Return on assets (ROA) | 0.14 | 0.18 |
| Return on equity (ROE) | 0.12 | 0.15 |
Mid-year reports
non-audited, consolidated, IFRS; Business Year: January 1 - December 31| Key P&L Figures | Jan 2024 - Jun 20241 | Jan 2025 - Jun 20251 |
|---|---|---|
| (million HUF) | (million HUF) | |
| Net sales | 419,693 | 465,509 |
| Operating profit (EBIT) | 137,964 | 140,384 |
| Net income from financial activities | 24,242 | 3,176 |
| Profit before tax | 168,108 | 145,055 |
| Profit after tax | 150,287 | 120,111 |
| Key Balance Sheet Items | 30 Jun 2024 | 30 Jun 2025 |
|---|---|---|
| (million HUF) | (million HUF) | |
| Fixed Assets | 912,809 | 911,096 |
| Intangible Assets | 335,467 | 330,191 |
| Tangible assets | 359,921 | 378,137 |
| Invested financial assets | 185,208 | 161,083 |
| Current Assets | 545,884 | 689,957 |
| Inventory | 205,752 | 223,330 |
| Total assets | 1,458,693 | 1,601,053 |
| Shareholders equity | 1,184,695 | 1,302,179 |
| Share capital | 18,638 | 18,638 |
| Long-term liabilities | 118,176 | 123,123 |
| Short-term liabilities | 155,822 | 175,751 |
| Total liabilities and shareholders equity | 1,458,693 | 1,601,053 |
- (1) non-audited, consolidated, IFRS; Business Year: January 1 - December 31
| Shareholders exceeding 5% stake with respect to the listed series | ||
|---|---|---|
| Name | Shareholding (%) | Share piece |
| Maecenas Universitatis Corvini Alapítvány | 10.00 | 18,637,486 |
| Mathias Corvinus Collegium Alapítvány | 10.00 | 18,637,486 |
| Nemzeti Egészségügyi és Orvosképzésért Alapítvány | 5.25 | 9,777,658 |
| FMR LLC | 5.07 | 9,457,941 |
| Free Float: 69.68% | Last update: 28 Feb 2025 | |
| Note: When determining the Free Float for a particular series, all the securities of the company shall be regarded to be publicly held other than (i) the stock of securities held by holders with direct holdings of more than 5% of the total number of securities, (ii) securities in the possession of custodians, provided the certificate available to the custodian verifies that the particular person holds more than 5% of the total number of securities outstanding belonging to the series. The value of the free float is based on the data provided by the issuer. | ||
| Management | |
|---|---|
| Management Board | BOGSCH Erik (Honorary President), ORBÁN Gábor, Dr. PINTÉRNÉ dr. HARDY Ilona (Deputy President of the Board), Prof. Dr. VIZI Elek Szilveszter (President of the Board), Dr. PANDURICS Anett (Deputy President of the Board), SZÉCSÉNYI Bálint, Dr. CSERHÁTI Péter, Prof. Dr. ÁCS Nándor, KOVÁCS László András, BALOGH Gabriella, SZEPESI Balázs, NÉMETH Lászlóné |
| Management | ORBÁN Gábor (CEO), Dr. GREINER István (Research and Development Director), KOVÁCS László András (CFO), ERDEI Katalin (Director of Human Resources and Technical activities), SZOLYÁK Tamás (Commercial Director), SZÉNÁSI Attila (Director of Production ang Logistic activities) |
| Supervisory Board | Dr. BEDROS Jonathán Róbert, Dr. PAVLIK Lívia, Dale André MARTIN, Dr. GÁL Krisztina, SALLAI Ferenc, CSEPREGI Gábor |
| Last update: 17 Jul 2025 | |
| Publication | News |
|---|---|
| 27 Aug 2025 17:30 | The European Commission approves Bio-Thera’s BAT2206 (USYMRO®, a biosimilar ustekinumab), to be commercialized by Richter in Europe |
| 06 Aug 2025 10:00 | 2025 Half-yearly Report |
| 31 Jul 2025 14:10 | Voting rights, registered capital |
| 24 Jul 2025 09:55 | Transactions with Treasury Shares |
| 03 Jul 2025 16:05 | Articles of Associations |
| 01 Jul 2025 08:00 | Richter receives European Commission approval for Junod® and Yaxwer®, its biosimilar denosumab products for bone disease and osteoporosis |
| 30 Jun 2025 14:15 | Voting rights, registered capital |
| 13 Jun 2025 09:55 | Transactions with Treasury Shares |
| 11 Jun 2025 08:00 | Richter agrees on voluntary price restriction |
| 06 Jun 2025 14:45 | Statutes |
| Publication | Report |
|---|---|
| 26 Apr 2024 15:20 | Annual Report approved by Gedeon Richter Plc.'s Annual General Meeting on April 25, 2024 (ZIP) |
| 06 Aug 2025 10:00 | 2025 Half-yearly Report |
| 26 Apr 2024 15:11 | Gedeon Richter Plc.'s Corporate Governance Report from year 2023 |
| Publication | Articles of Association |
|---|---|
| 03 Jul 2025 16:05 | Articles of Associations |
| Publication | Voting rights, registered capital |
|---|---|
| 31 Jul 2025 14:10 | Voting rights, registered capital |
| Publication | Corporate Action Timetable |
|---|---|
| 10 Dec 2024 10:50 | Corporate Action Timetable |
| Name of security | Richter Gedeon share |
| Issuer | Chemical Works of Gedeon Richter Plc. |
| Equity class | Ordinary share |
| Type of security | Registered |
| Form of security | Dematerialised |
| Code of security (ISIN) | HU0000123096 |
| Ticker symbol | RICHTER |
| Face value | 100 HUF |
| Number of securities listed | 186,374,860 |
| Rights to dividends | Full year |
| Listing date | 09 Nov 1994 |
| First Trading Day | 09 Nov 1994 |
| Market | Prime |
| Trading Unit | |
| Currency of trading | HUF |
| Trading time | |
| Listing price | 1,330 |